NASDAQ : RAPP
Rapport Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 25.05 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 1.48B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.49B |
| Enterprise Value | 1.06B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 59.17M |
| Shares Outstanding | 59.17M |
| Shares Change (YoY) | +27.52% |
| Shares Change (QoQ) | +0.50% |
| Owned by Insiders (%) | 3.39% |
| Owned by Institutions (%) | 69.01% |
| Float | 46.18M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 74.35 |
| Forward PS | 22,302.55 |
| PB Ratio | 2.85 |
| P/TBV Ratio | 3.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 53.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 15.72 |
| Quick Ratio | 15.35 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -39.96% |
| Return on Assets (ROA) | -25.78% |
| Return on Invested Capital (ROIC) | -27.09% |
| Return on Capital Employed (ROCE) | -35.66% |
| Weighted Average Cost of Capital (WACC) | 10.88% |
| Revenue Per Employee | $238,095 |
| Profits Per Employee | -$1.63M |
| Employee Count | 84 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.22 |
| 52-Week Price Change | -13.14% |
| 50-Day Moving Average | 36.24 |
| 200-Day Moving Average | 35.64 |
| Relative Strength Index (RSI) | 37.81 |
| Average Volume (20 Days) | 1,444,809 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.05M |
| Short Previous Month | 3.19M |
| Short % of Shares Out | 5.16% |
| Short % of Float | 6.61% |
| Short Ratio (days to cover) | 6.70 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 20.00M |
| Gross Profit | -21.88M |
| Operating Income | -153.52M |
| Pretax Income | -137.16M |
| Net Income | -137.16M |
| EBITDA | -152.56M |
| EBIT | -153.52M |
| Loss Per Share | -$3.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 436.08M |
| Total Debt | 10.11M |
| Net Cash | 425.97M |
| Net Cash Per Share | $7.20 |
| Equity (Book Value) | 422.93M |
| Book Value Per Share | 8.82 |
| Working Capital | 418.43M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -96.68M |
| Capital Expenditures | -467,000 |
| Depreciation & Amortization | 960,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -97.15M |
| FCF Per Share | -$1.64 |
Margins
| Measure | Value |
|---|
| Gross Margin | -109.39% |
| Operating Margin | -767.58% |
| Pretax Margin | -685.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -27.52% |
| Shareholder Yield | -27.52% |
| Earnings Yield | -12.15% |
| FCF Yield | -6.53% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $68.29 |
| Price Target Difference | 171.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 20.27 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |